Plné znění - 454/2009 Sb.

Nařízení vlády

§1  §2  §3  §4

Příloha č. 1 - Látky s anabolickým a jiným hormonálním účinkem

Příloha č. 2 - Metody s dopingovým účinkem

INFORMACE

454

XXXXXXXX XXXXX

xx xxx 7. xxxxxxxx 2009,

xxxxxx xx xxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxx, xx xx xxxxxxxx xx xxxxx x xxxxxxxxxxx x xxxxx xxxxxxxxxxx účinkem a xxxx je xxxxxx xxxxx xxxxxxxx, a xx xx xxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx za xxxxxx xxxxxxxxxxx ve xxxxxxxxx xxxxxxx xxxxxxx x xxxxxxx xxxxxxxxx a xx jiné xxxxxx x xxxxxxxxxx účinkem
 

Vláda xxxxxxxx xxxxx §289 xxxx. 4 xxxxxx x. 40/2009 Sb., xxxxxxx xxxxxxx:

§1

Za xxxxx s xxxxxxxxxxx x jiným xxxxxxxxxxx xxxxxxx ve xxxxxx §288 xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx, xxxxx jsou xxxxxxx x příloze č. 1 x xxxxxx xxxxxxxx.

§2

Větším xxxxxxxxx xx x xxxxx s xxxxxxxxxxx x xxxxx xxxxxxxxxxx xxxxxxx xx xxxxxx §288 xxxxxxxxx xxxxxxxx xxxxxx více xxx xxxxx xxxxxx, xxxxxxx xxxx podobné xxxxxxx nedělitelné xxxxxx xxxx xxxxxxxxxxxx tyto xxxxx xxxx xxxxxxx xxxxxxxx xxxxxx xxxxx xx xxxxxxxxxx dopingovém xxxxxxxxx.

§3

Xx metodu xxxxxxxxxxx xx xxxxxxxxx xxxxxxx xxxxxxx v xxxxxxx xxxxxxxxx a za xxxx xxxxxx s xxxxxxxxxx účinkem xx xxxxxx §288 xxxxxxxxx xxxxxxxx se xxxxxxxx xxxxxx, které xxxx xxxxxxx x příloze č. 2 x xxxxxx nařízení.

§4

Xxxx xxxxxxxx xxxxxx xxxxxxxxx xxxx 1. xxxxx 2010.

Předseda vlády:

Ing. Xxxxxxx, CSc. x. x.

Xxxxxxxxxx spravedlnosti:

JUDr. Xxxxxxxx x. x.

Xxxxxxx x. 1 x xxxxxxxx xxxxx x. 454/2009 Sb.

Látky x xxxxxxxxxxx x xxxxx xxxxxxxxxxx účinkem

A. XXXXXXXXXX XXXXX

X.1 Androgenní xxxxxxxxxx xxxxxxxx (XXX)

x) xxxxxxxx XXX

1. 1-xxxxxxxxxxxxx (5x-xxxxxxx-1-xx-3x,17x-xxxx);

2. 1-xxxxxxxxxxxxx (5a-androst-1-en-3,17-dion);

3. 1-xxxxxxxxxxx (17x-xxxxxxx-5x-xxxxxxx-1-xx-3-xx);

4. 4-hydroxytestosteron (4,17x-xxxxxxxxxxxxxxxx-4-xx-3-xx);

5. 19-norandrostendion (estr-4-en-3,17-dion);

6. xxxxxxxxx (19-xxxxxxxxxxxxxxxx);

7. xxxxxxxxxx;

8. xxxxxxxx;

9. xxxxxxx (androsta-1,4-dien-3,17-dion);

10. xxxxxxx (17x-xxxxxxx-17x-xxxxxxxxxxxxxx-4-xxx [2,3-x] xxxxxxxx);

11. xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17x-xxxxxxx-17x-xxxxxxxxxxxxxx-1,4-xxxx-3xx);

12. xxxxxxxxxxxxxxxxxxxxxxx (17x-xxxxxx-5x-xxxxxxx-2-xx-17x-xx);

13. xxxxxxxxxxx;

14. xxxxx-4,9-xxxx-3,17-xxxx (19-xxxxxxxxxxx-4,9-xxxx-3,17-xxxx);

15. xxxxxxxxxxxxx (19-xxx-17x-xxxxx-4-xx-17-xx);

16. xxxxxxxxxxxxxx;

17. xxxxxxxxxx;

18. xxxxxxxxx (17x-xxxxxxx-17x-xxxxxx-5x-xxxxxxxxxx [2,3-c]-furazan);

19. xxxxxxxxx;

20. xxxxxxxxxx;

21. xxxxxxxxx;

22. xxxxxxxxxx;

23. xxxxxxxxxx;

24. xxxxxxxxxxx (17x-xxxxxxx-17x-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

25. methandriol;

26. xxxxxxxxxxx (2x, 17x-xxxxxxxx-5x-xxxxxxxxx-3-xx-17x-xx);

27. xxxxxxxxx;

28. xxxxxx-1-xxxxxxxxxxx (17x-xxxxxxx-17x-xxxxxx-5x-xxxxxxx-x-xx-3-xx);

29. methyldienolon (17x-xxxxxxx-17x-xxxxxxxxxxx-4,9-xxxx-3-xx);

30. xxxxxxxxxxxxxxxxxxxx (17x-xxxxxxx-17x-xxxxxxxxxx-4-xx-3-xx);

31. xxxxxxxxxxxxxxxxx;

32. methyltrienolon (17x-xxxxxxx-17x-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

33. xxxxxxxxx;

34. xxxxxxxxx;

35. norboleton;

36. xxxxxxxxxxxx;

37. norethandrolon;

38. xxxxxxxx;

39. xxxxxxxxxx;

40. oxymesteron;

41. oxymetholon;

42. xxxxxxxxxxx ([3,2-x]xxxxxxx-5x-xxxxxxxxxxxxxx-17x-xxxxxxxxxxxxxxxxx);

43. xxxxxxxxx;

44. xxxxxxxxxx;

45. xxxxxxxxx;

46. xxxxxxxxxxxxxxxxxxx (18x-xxxx-xxxxxx-4,9,11-xxxxx-17x-xx-3-xx);

47. trenbolon;

48. další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx;

x) xxxxxxxxx XXX

1. 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3x, 17b-diol);

2. 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3, 17-xxxx);

3. 19-norandrosteron;

4. 19-xxxxxxxxxxxxxxxxx;

5. 3a-hydroxy-5a-androstan-17-on;

6. 3b-hydroxy-5a-androstan-17-on;

7. 5x-xxxxxxxxx-3x, 17x-xxxx;

8. 5a-androstan-3a, 17x-xxxx;

9. 5a-androstan-3b, 17a-diol;

10. 5x-xxxxxxxxx-3x, 17b-diol;

11. androst-4-en-3a, 17x-xxxx;

12. xxxxxxx-4-xx-3x, 17b-diol;

13. xxxxxxx-5-xx-3x, 17x-xxxx;

14. xxxxxxx-5-xx-3x, 17x-xxxx;

15. androst-5-en-3b, 17x-xxxx;

16. xxxxxxxxxxxxx (androst-5-en-3b, 17x-xxxx);

17. xxxxxxxxxxxxx (xxxxxxx-4-xx-3, 17-dion);

18. xxxxxxxxxxxxxxxxxx;

19. epi-dihydrotestosteron;

20. xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx DHEA);

21. testosteron;

22. xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X.2 Ostatní xxxxxxxxxx xxxxx

1. klenbuterol;

2. xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), například:

2.1 xxxxxxxxx (XXX-40233);

3. xxxxxxx;

4. xxxxxxx;

5. xxxxxxxxxx;

6. xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

X. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX LÁTKY X XXXXXXXX

X.1 Látky stimulující xxxxxxxxxxx

x) xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx:

1. xxxxxxxxxxxx (xXXX);

2. erytropoetiny (XXX);

3. xxxxxxxxxx založené xx XXX, například:

3.1 XXX-Xx;

3.2 xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA);

4. XXX-xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxxxxxxx:

4.1 XXXX 530;

4.2 xxxxxxxxxxx;

x) xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxx:

1. xxxxxxxxxxx (XXX1278863);

2. XXX2 xxxxxxxxxx (XXX 85-3934);

3. xxxxxxxxxx (FG-4592);

4. xxxxxxxxxx (XXX-6548);

x) inhibitory XXXX, xxxxxxxxx: 1. X-11706;

x) xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX - β), xxxxxxxxx:

1. luspatercept;

2. xxxxxxxxxxx.

X.2 Xxxxxxxxx xxxxxxx x jejich xxxxxxxxxx xxxxxxx

x) xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) a xxxxxx xxxxxxxxxx xxxxxxx

1. buserelin;

2. xxxxxxxxxx;

3. gonadorelin;

4. xxxxxxxxx;

5. xxxxxxxxxxx;

6. xxxxxxxxx;

7. triptorelin;

b) xxxxxxxxxxxxxx, xxxxxx xxxxxxxxxx xxxxxxx;

x) růstový xxxxxx (XX), xxxx fragmenty x xxxxxxxxxx xxxxxxx

1. xxxxxxxxx růstového xxxxxxx, xxxxxxxxx:

1.1 XXX-9604;

1.2 xXX 176-191;

2. xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx xxxxxxx, xxxxxxxxx:

2.1 XXX-1293;

2.2 CJC-1295;

2.3 XXX-1295 XXX;

2.4 xxxxxxxxx;

2.5 xxxxxxxxxx;

2.6 sermorelin;

2.7 xxxxxxxxxxx;

2.8 xxxxxxxxxxx;

x) xxxxxxxxxxx růstového xxxxxxx (GHS) x xxxxxxxx ghrelinového xxxxxxxxx, xxxxxxxxx:

1. anamorelin;

2. ibutamoren (XX-677);

3. xxxxxxxxxx (XXX 26-0161);

4. xxxxxxxxxxx (ghrelin);

5. xxxxxxxxxxx;

6. tabimorelin;

e) xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx XX (XXXX), například:

1. xxxxxxxxxxxx;

2. examorelin (hexarelin);

3. XXXX-1;

4. XXXX-2 (xxxxxxxxxxx);

5. XXXX-3;

6. XXXX-4;

7. XXXX-5;

8. XXXX-6;

x) další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X.3 Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx

x) xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGF);

b) xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

x) xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x xxxx xxxxxxx;

x) xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

x) xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX);

x) xxxxxxxx-β4 x xxxx deriváty, xxxxxxxxx:

1. XX-500;

x) xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF);

h) xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

X. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

X.1 Xxxxxxxxxx xxxxxxxx

1. xxxxxxxxxxxxxxxx;

2. anastrozol;

3. xxxxxxxxx;

4. xxxxxxxxx;

5. xxxxxxxx;

6. xxxxxxxxxxx;

7. xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X.2 Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX)

1. xxxxxxxxx;

2. xxxxxxxxx;

3. xxxxxxxxx;

4. xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X.3 Xxxxxxx xxxxxxxxxxxxxx xxxxx

1. cyklofenil;

2. xxxxxxxxxxx;

3. klomifen;

4. xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

C.4 Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx

X.5 Xxxxxxxxxxx xxxxxxxxxx

x) xxxxxxxxxx AMP-aktivované proteinkinázy (XXXX), xxxxxxxxx:

1. AICAR;

b) xxxxxxxx receptoru δ xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxxxxxxx:

1. xxxxxxxx (XX1516, XX501516, endurobol);

c) xxxxxxxx a xxxxxxxx xxxxxxxx;

x) xxxxxxxxx;

x) xxxxxxxx Xxx-XxxX, xxxxxxxxx:

1. Stenabolic (XX9009);

x) další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X.6 Xxxxxxxxxx xxxxxxxxxxx xxxxxxx

x) syntetická xxxxxxx α-XXX, xxxxxxxxx:

1. xxxxxxxxxxxx;

2. melanotan X (xxxxxxxxxxxx);

3. melanotan XX;

x) xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

Xxxxxxx x. 2 x xxxxxxxx vlády x. 454/2009 Xx.

Xxxxxx x dopingovým xxxxxxx

X. XXXXXXXXX PŘENOSU XXXXXXX

1. Xxxxxx xxxxxx xxxxxx xxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx produkty (např. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13) a xxxxx produkty x xxxxxxxx xxxxxxx.

X. XXXXXX XXXXXX

1. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx x potenciálem xxxxxx sportovní xxxxx.

2. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx analogů, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxx například technologie xxxxx genů, umlčování xxxx x xxxxxxxxxxx xxxxxxx genů.

Právní xxxxxxx x. 454/2009 Sb. xxxxx xxxxxxxxx xxxx 1.1.2010.

Ve xxxxx xxxxxx xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxx x.:

2/2012 Xx., kterým xx xxxx xxxxxxxx xxxxx x. 454/2009 Xx., xxxxxx xx xxx xxxxx trestního xxxxxxxx xxxxxxx, xx xx xxxxxxxx za xxxxx x xxxxxxxxxxx x xxxxx xxxxxxxxxxx xxxxxxx x jaké xx xxxxxx xxxxx xxxxxxxx, x xx xx xxx účely xxxxxxxxx zákoníku xxxxxxxx xx xxxxxx xxxxxxxxxxx xx xxxxxxxxx xxxxxxx xxxxxxx x xxxxxxx xxxxxxxxx a xx xxxx xxxxxx s xxxxxxxxxx účinkem

s xxxxxxxxx xx 5.1.2012

359/2021 Xx., xxxxxx xx xxxx xxxxxxxx xxxxx x. 454/2009 Xx., kterým xx xxx účely xxxxxxxxx xxxxxxxx xxxxxxx, xx xx xxxxxxxx xx xxxxx x xxxxxxxxxxx a jiným xxxxxxxxxxx xxxxxxx x xxxx je xxxxxx xxxxx množství, x xx se pro xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx za xxxxxx xxxxxxxxxxx xx xxxxxxxxx xxxxxxx kyslíku v xxxxxxx xxxxxxxxx x xx xxxx metody x xxxxxxxxxx xxxxxxx, xx xxxxx xxxxxxxx xxxxx č. 2/2012 Xx.

x účinností od 1.1.2022

74/2025 Xx.,&xxxx;xxxxxx se xxxx xxxxxxxx xxxxx x. 454/2009 Xx., xxxxxx se xxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxx, co se xxxxxxxx xx látky x xxxxxxxxxxx x xxxxx xxxxxxxxxxx účinkem x xxxx xx xxxxxx větší množství, x co se xxx účely trestního xxxxxxxx považuje xx xxxxxx xxxxxxxxxxx ve xxxxxxxxx přenosu kyslíku x xxxxxxx xxxxxxxxx x xx xxxx xxxxxx x xxxxxxxxxx xxxxxxx, ve xxxxx xxxxxxxxxx xxxxxxxx

x xxxxxxxxx xx 1.7.2025

Xxxxx jednotlivých xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx x xxxxxxxx xxxx aktualizováno, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.